Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib Plus Duvelisib in ALK+ ALCL
NCT07001384Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2025
- Primary completion
- Aug 2031
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alectinib and duvelisib in anaplastic large cell lymphoma (ALCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Aug 2025; status: recruiting.
02
Drugs
alectinibduvelisib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT07001384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001384.